Transcriptome sequencing of malignant pleural mesothelioma tumors
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Cancers arise by the gradual accumulation of mutations in multiple genes. We now use shotgun pyrosequencing to characterize RNA mutations and expression levels unique to malignant pleural mesotheliomas (MPMs) and not present in control tissues. On average, 266 Mb of cDNA were sequenced from each of four MPMs, from a control pulmonary adenocarcinoma (ADCA), and from normal lung tissue. Previously observed differences in MPM RNA expression levels were confirmed. Point mutations were identified by using criteria that require the presence of the mutation in at least four reads and in both cDNA strands and the absence of the mutation from sequence databases, normal adjacent tissues, and other controls. In the four MPMs, 15 nonsynonymous mutations were discovered: 7 were point mutations, 3 were deletions, 4 were exclusively expressed as a consequence of imputed epigenetic silencing, and 1 was putatively expressed as a consequence of RNA editing. Notably, each MPM had a different mutation profile, and no mutated gene was previously implicated in MPM. Of the seven point mutations, three were observed in at least one tumor from 49 other MPM patients. The mutations were in genes that could be causally related to cancer and included XRCC6 , PDZK1IP1 , ACTR1A , and AVEN .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome sequencing in microfabricated high-density picolitre reactors
Margulies, M., Egholm, M., Altman, W. E., Attiya, S., Bader, J. S., Bemben, L. A., Berka, J., Braverman, M. S., Chen, Y.-J., Chen, Z., et al. (2005) · Nature · doi:10.1038/nature03959 · Cited by 7,693 · cited 5×
“These rules require that the variant must have at least four reads covering the base position; be present in at least 30% of the total number of reads covering the variant; be of GS20 quality score 20 (18) for the”
BackgroundMethodInfluentialSelf-citationJones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515 · cited 1×
“However, there has rarely been an analysis of whether a mutated gene is actually expressed in the tumor cell nor has there been an attempt to use sequencing to identify other types of mutations such as chromosomal deletions or translocation (4, 5) or loss of heterozygosity related to epigenetic silencing (6, 7).”
BackgroundGlobal variation in copy number in the human genome
Redon, R., Ishikawa, S., Fitch, K. R., Feuk, L., Perry, G. H., Andrews, T. D., Fiegler, H., Shapero, M. H., Carson, A. R., Chen, W., et al. (2006) · Nature · doi:10.1038/nature05329 · Cited by 4,288 · cited 1×
“This may variously reflect the homozygous presence of a SNP, preferential transcription/stability of one allele (24), or copy number variation (25).”
BackgroundThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080 · cited 2×
“By extrapolation to the 10,000 expressed Known RefSeq Genes detected in MPM transcriptomes (Table 1), it is estimated that individual MPM tumors harbor, on average, 6 transcribed genes with somatic mutations, or 10–14 genes with a nsSNV in the entire genome, in accord with a recent exon-resequencing survey of cancers…”
BackgroundStructure of the Ku heterodimer bound to DNA and its implications for double-strand break repair
Walker, J. R., Corpina, R. A., & Goldberg, J. (2001) · Nature · doi:10.1038/35088000 · Cited by 1,212 · cited 2×
“Of particular note, the protein product of XRCC6 (Ku70) forms a heterodimer with that of XRCC5 (Ku80) and mediates the repair of DNA double-strand breaks via nonhomologous end-joining.”
BackgroundThe proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201 · cited 1×
“The PSMD13 gene encodes subunit 11 of the 26S proteasome (36), which is the target of a new class of anticancer drugs (37).”
BackgroundCharacterizing the cancer genome in lung adenocarcinoma
Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105
Self-citationGordon, G. J., Jensen, R. V., Hsiao, L.-L., Gullans, S. R., Blumenstock, J. E., Ramaswamy, S., Richards, W. G., Sugarbaker, D. J., & Bueno, R. (2002) · PubMed · Cited by 948
Self-citationAnalysis of one million base pairs of Neanderthal DNA
Green, R. E., Krause, J., Ptak, S. E., Briggs, A. W., Ronan, M. T., Simons, J. F., Du, L., Egholm, M., Rothberg, J. M., Paunovic, M., et al. (2006) · Nature · doi:10.1038/nature05336 · Cited by 760 · cited 1×
“Newly developed DNA sequencing technologies (18, 19) allow for rapid, less expensive sequencing of large and complex genomes, but their utility in cancer mutation discovery remains unproved.”
BackgroundSelf-citationYang, H., Bocchetta, M., Kroczynska, B., Elmishad, A. G., Chen, Y., Liu, Z., Bubici, C., Mossman, B. T., Pass, H. I., Testa, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604008103 · Cited by 322
Aven, a Novel Inhibitor of Caspase Activation, Binds Bcl-xL and Apaf-1
CHAU, B. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00005-8 · Cited by 213 · cited 1×
“The genetic lesion identified in AVEN is of potential interest because this gene impairs Apaf-1-mediated activation of caspases, and thus apoptosis (39).”
BackgroundDynamin Participates in Focal Extracellular Matrix Degradation by Invasive Cells
Baldassarre, M., Pompeo, A., Beznoussenko, G., Castaldi, C., Cortellino, S., McNiven, M. A., Luini, A., & Buccione, R. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-05-0308 · Cited by 212
Haber, D. A., & Settleman, J. (2007) · Nature · doi:10.1038/446145a · Cited by 203 · cited 1×
“However, there has rarely been an analysis of whether a mutated gene is actually expressed in the tumor cell nor has there been an attempt to use sequencing to identify other types of mutations such as chromosomal deletions or translocation (4, 5) or loss of heterozygosity related to epigenetic silencing (6, 7).”
BackgroundGordon, G. J., Rockwell, G. N., Jensen, R. V., Rheinwald, J. G., Glickman, J. N., Aronson, J. P., Pottorf, B. J., Nitz, M. D., Richards, W. G., Sugarbaker, D. J., et al. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62492-3 · Cited by 194
Self-citationThe epidemiology of mesothelioma
Britton, M. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30237 · Cited by 186
Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2
Fischer, H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.875 · Cited by 180 · cited 1×
“COL5A2 encodes the -chain for a low-abundance fibrillar collagen that is up-regulated in colon cancer (33) and normally has antitumor effects in breast cancer, including the induction of apoptosis (34).”
BackgroundZou, T.-T., Selaru, F. M., Xu, Y. H., Shustova, V., Yin, J., Mori, Y., Shibata, D., Sato, F., Wang, S., Olaru, A., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205613 · Cited by 158 · cited 1×
“Although functionally uncharacterized, MXRA5 is overexpressed in colon cancer (38).”
BackgroundAn atlas of human gene expression from massively parallel signature sequencing (MPSS)
Jongeneel, C. V., Delorenzi, M., Iseli, C., Zhou, D., Haudenschild, C. D., Khrebtukova, I., Kuznetsov, D., Stevenson, B. J., Strausberg, R. L., Simpson, A. J. G., et al. (2005) · Genome Research · doi:10.1101/gr.4041005 · Cited by 158 · cited 1×
“’’ A prior study using massively parallel signature sequencing (MPSS) of mRNAs in human tissues concluded that 50% of the genes in the human genome are expressed in a tissue (21).”
BackgroundHsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus
Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., & Pratt, W. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402223200 · Cited by 150 · cited 1×
“ACTR1A encodes the most abundant subunit of dynactin, which is associated with transport of p53 to the nucleus (29).”
BackgroundKocher, O. N., Comella, N., Gilchrist, A., Pal, R., Tognazzi, K., Brown, L. F., & Knoll, J. H. M. (1999) · PubMed · Cited by 137
Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
Kaminker, J. S., Zhang, Y., Waugh, A., Haverty, P. M., Peters, B., Sebisanovic, D., Stinson, J., Forrest, W. F., Bazan, J. F., Seshagiri, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1736 · Cited by 126 · cited 1×
“This specific amino acid substitution could be a cancer-driver mutation based on computational analysis of protein domain structure (28).”
BackgroundLee, M.-N., Tseng, R.-C., Hsu, H.-S., Chen, J.-Y., Tzao, C., Ho, W. L., & Wang, Y.-C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2694 · Cited by 124 · cited 2×
“In non-small-cell lung cancer XRCC5 is often hypermethylated and underexpressed at the mRNA and protein levels and is generally correlated with p53 changes (5).”
BackgroundKyt�l�, S., Rummukainen, J., Nordgren, A., Karhu, R., Farnebo, F., Isola, J., & Larsson, C. (2000) · Genes, Chromosomes and Cancer · doi:10.1002/1098-2264(200007)28:3<308::aid-gcc9>3.0.co;2-b · Cited by 116
Cytogenetic and molecular genetic changes in malignant mesothelioma
Musti, M., Kettunen, E., Dragonieri, S., Lindholm, P., Cavone, D., Serio, G., & Knuutila, S. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.04.011 · Cited by 108
Balsara, B., Bell, D. W., Sonoda, G., Rienzo, A. D., du Manoir, S., Jhanwar, S. C., & Testa, J. R. (1999) · PubMed · Cited by 77
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma
Gordon, G. J., Appasani, K., Parcells, J. P., Mukhopadhyay, N. K., Jaklitsch, M. T., Richards, W. G., Sugarbaker, D. J., & Bueno, R. (2002) · Carcinogenesis · doi:10.1093/carcin/23.6.1017 · Cited by 75 · cited 1×
“In addition, tumor cell survival promoted by TNF- responsive antiapoptotic proteins such as Inhibitor of Apoptosis-1 (IAP-1) facilitates the resistance of MPM to most cytotoxic chemotherapeutic drugs (16).”
BackgroundSelf-citationKocher, O. N., Cheresh, P., & Lee, S. W. (1996) · Europe PMC (PubMed Central) · Cited by 70
Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma
Gordon, G., Mani, M., Mukhopadhyay, L., Dong, L., Edenfield, H., Glickman, J. N., Yeap, B. Y., Dj, S., & Bueno, R. (2007) · The Journal of Pathology · doi:10.1002/path.2121 · Cited by 70
Self-citationGordon, G., Mani, M., Mukhopadhyay, L., Dong, L., Yeap, B., Sugarbaker, D., & Bueno, R. (2007) · The Journal of Pathology · doi:10.1002/path.2120 · Cited by 68 · cited 1×
“Expression profiling with microarrays has supported the general role of inflammation in MPM etiology and has provided molecular markers for diagnosis and prognosis (17).”
BackgroundSelf-citationKulawiec, M., & Arnouk, H. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.2880 · Cited by 64
Identification of RNA editing sites in the SNP database
Eisenberg, E., Adamsky, K., Cohen, L., Amariglio, N., Hirshberg, A., Rechavi, G., & Levanon, E. Y. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki771 · Cited by 63 · cited 2×
“, a posttranscriptional process that alters the information encoded in gene transcripts, in this case a nsSNV present in the mRNA but not the gDNA) have been previously linked to cancer but not MPM (45).”
BackgroundSurvivin and aven: two distinct antiapoptotic signals in acute leukemias
Paydaş, S., Tanrıverdi, K., Yavuz, S., Dişel, U., Şahin, B., & Burgut, R. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg277 · Cited by 58 · cited 1×
“We and others (9, 15–17, 40) have previously identified other (non-Bcl-2) antiapoptotic survival pathways as being particularly important in MPM tumorigenesis and drug resistance, and AVEN was recently implicated in acute leukemias (41).”
BackgroundRNA regulation and cancer development
Scholzová, E., Malík, R., Ševčík, J., & Kleibl, Z. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.03.021 · Cited by 57 · cited 2×
“The actual editing is site-specific and occurs through specific mechanisms that are thought to be altered in cancers (44).”
BackgroundKocher, O. N., Cheresh, P., Brown, L. F., & Lee, S. W. (1995) · PubMed · Cited by 57
Kristiansen, M. B., Knudsen, G. P. S., Maguire, P., Margolin, S., Pedersen, J., Lindblom, A., & Ørstavik, K. H. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.032433 · Cited by 48 · cited 1×
“Although less well studied than somatic mutations and LOH, both X chromosome inactivation (42, 43) and RNA editing (44) (i.”
BackgroundMolecular pathways in malignant pleural mesothelioma
Whitson, B. A., & Kratzke, R. A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.08.010 · Cited by 46
Luparello, C., & Sirchia, R. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20131 · Cited by 46 · cited 1×
“COL5A2 encodes the -chain for a low-abundance fibrillar collagen that is up-regulated in colon cancer (33) and normally has antitumor effects in breast cancer, including the induction of apoptosis (34).”
BackgroundGenetic factors in the aetiology of malignant mesothelioma
Huncharek, M. S. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00365-p · Cited by 41
Somatic Mutations in Human Cancer: Insights from Resequencing the Protein Kinase Gene FamilyPreprint
Futreal, P. A., Wooster, R., & Stratton, M. R. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.015 · Cited by 32
Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma
Rienzo, A. D., Jhanwar, S. C., & Testa, J. R. (2000) · Genes Chromosomes and Cancer · Cited by 30
Pylkkänen, L., Sainio, M. A., Ollikainen, T., Mattson, K. V., Nordling, S., Carpén, O., Linnainmaa, K., & Husgafvel‐Pursiainen, K. (2002) · Oncology Reports · doi:10.3892/or.9.5.955 · Cited by 29
Proteomic analysis of mitochondria-to-nucleus retrograde response in human cancer cells
Kulawiec, M., Arnouk, H., Desouki, M. M., Kazim, L., Still, I. H., & Singh, K. K. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.08.039 · Cited by 26
Li, G., Su, Q., Liu, G.-Q., Gong, L., Zhang, W., Zhu, S.-J., Zhang, H., & Feng, Y.-M. (2006) · Oncology Reports · doi:10.3892/or.16.4.859 · Cited by 24 · cited 1×
“Although less well studied than somatic mutations and LOH, both X chromosome inactivation (42, 43) and RNA editing (44) (i.”
BackgroundBenz, C. C., Fedele, V., Xu, F., Ylstra, B., Ginzinger, D. G., Yu, M., Moore, D. H., Hall, R. K., Wolff, D. J., Disis, M. L., et al. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20364 · Cited by 12 · cited 1×
“This may variously reflect the homozygous presence of a SNP, preferential transcription/stability of one allele (24), or copy number variation (25).”
BackgroundRichards, W., Oss, S. V., Glickman, J. N., Chirieac, L. R., Yeap, B. Y., Dong, L., Gordon, G., Mercer, H., Gill, K., Imrich, A., et al. (2007) · Biotechnic & Histochemistry · doi:10.1080/10520290701488121 · Cited by 10
Self-citationIdentification, molecular cloning, and characterization of subunit 11 of the human 26S proteasome
Hoffman, L. M., Gorbea, C. M., & RECHSTEINER, M. C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00403-2 · Cited by 5 · cited 1×
“The PSMD13 gene encodes subunit 11 of the 26S proteasome (36), which is the target of a new class of anticancer drugs (37).”
Background
Cited by
Next-generation DNA sequencing
Shendure, J., & Ji, H. (2008) · Nature Biotechnology · doi:10.1038/nbt1486 · Cited by 4,509
RNA-seq: An assessment of technical reproducibility and comparison with gene expression arrays
Marioni, J. C., Mason, C. E., Mane, S. M., Stephens, M., & Gilad, Y. (2008) · Genome Research · doi:10.1101/gr.079558.108 · Cited by 2,771
“Although several papers have described the use of 454 sequencing to examine mRNA expression levels (Weber et al. 2007; Sugarbaker et al. 2008; Torres et al. 2008), we chose the Illumina sequencing platform because currently, for a fixed cost, its coverage and depth are far 6These authors contributed equally to this wo…”
BackgroundWhy do viruses cause cancer? Highlights of the first century of human tumour virology
Moore, P. S., & Chang, Y. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2961 · Cited by 745
Carrier testing for severe childhood recessive diseases by next-generation sequencing
Bell, C. J., Dinwiddie, D. L., Miller, N. A., Hateley, S. L., Ganusova, E. E., Mudge, J., Langley, R. J., Zhang, L., Lee, C. C., Schilkey, F. D., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001756 · Cited by 706
“Clinical metrics On the basis of these strategies and our previous experience of genotyping variants identified in next-generation genome and chromosome sequences (20, 21, 33, 34), a bioinformatic decision tree for genotyping disease mutations was developed (Fig.”
MethodSelf-citationRNA-seq: from technology to biology
Marguerat, S., & Bähler, J. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0180-6 · Cited by 531
Metadata
- Authors
- Sugarbaker, D. J., Richards, W. G., Gordon, G. J., Dong, L., De Rienzo, A., Maulik, G., Glickman, J. N., Chirieac, L. R., Hartman, M.-L., Taillon, B. E., Du, L., Bouffard, P., Kingsmore, S. F., Miller, N. A., Farmer, A. D., Jensen, R. V., Gullans, S. R., & Bueno, R.
- Affiliations
- *International Mesothelioma Program,
- Brigham and Women's Hospital (US)
- 454 Life Sciences, Inc., 20 Commercial Street, Branford, CT 06405;
- National Center for Genome Resources (US)
- Virginia Tech (US)
- RxGen, Inc., 100 Deepwood Drive, Hamden, CT 06517
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-03-04
- Volume
- 105
- Issue
- 9
- Pages
- 3521-3526
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2265129
- OpenAlex
- W2084180192
- Cited by
- 155
- References
- 47
- Citations by year
- 2024: 3 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 7 · 2019: 4 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 10 · 2014: 7 · 2013: 6 · 2012: 11
- FWCI
- 24.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion)
- Funders
- National Cancer Institute (R21/R33 CA 100315, P20CA9057801-A1, U01 CA65170-07, CA65170, R33CA100315, R21CA100315, U24CA114725, U01CA065170, R01CA120528)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Keywords
- malignant pleural mesothelioma, tumor transcriptome, RNA mutations, point mutations, non-synonymous mutations, RNA editing, epigenetic silencing, tumor-specific gene expression, Ku70, PDZK1IP1, Aven
- MeSH terms
- Ku Autoantigen, DNA-Binding Proteins, Humans, Membrane Proteins, Mesothelioma, Mutation, Neoplasm Proteins, Pleural Neoplasms, RNA, Neoplasm, Gene Expression Regulation, Neoplastic, Point Mutation, Sequence Deletion, RNA Editing, Gene Silencing, Gene Expression Profiling, Activin Receptors, Type I, Antigens, Nuclear, Adaptor Proteins, Signal Transducing, Apoptosis Regulatory Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.